Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Jul;68(1):195–200. doi: 10.1038/bjc.1993.313

Prognosis after resection of residual masses following chemotherapy for metastatic nonseminomatous testicular cancer: a multivariate analysis.

E W Steyerberg 1, H J Keizer 1, J Zwartendijk 1, G L Van Rijk 1, C J Van Groeningen 1, J D Habbema 1, G Stoter 1
PMCID: PMC1968324  PMID: 8318413

Abstract

Following chemotherapy for metastatic nonseminomatous testicular cancer, 86 patients with normal serum markers AFP and HCG underwent resection of residual tumour masses (63 laparotomy, 11 thoracotomy, 12 both). Prognostic factors for relapse and survival were analysed with Kaplan-Meier curves and Cox regression analysis. Putative prognostic factors included age, the primary histology, prechemotherapy level of the tumour markers AFP and HCG, the extent of disease (lymph nodes, lung and hepatic metastases) before and after chemotherapy, the histology of the resected material and the completeness of the surgical procedure. Eleven patients relapsed during follow-up (median 47 months), accounting for a 5 year relapse free percentage of 87.4%. Adverse prognostic factors were (1) prechemotherapy level of HCG (> or = 10,000 IU l-1; (2) incomplete resection; and (3) the extent of disease, especially of lung metastases (prechemotherapy number < or = 3,4-19, > or = 20; or size after chemotherapy > 1 cm; or presence of any residual lung metastasis after chemotherapy without residual abdominal metastases). The histology found at resection was not associated with the risk of relapse, which might be explained by the effectiveness of postresection chemotherapy, which in the majority of these patients was a salvage regimen rather than two further cycles of the initial cytostatics. A good and a poor risk group were formed, based on HCG level and completeness of resection. The effect of salvage chemotherapy after resection of viable cancer cells needs further investigation.

Full text

PDF
195

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aass N., Klepp O., Cavallin-Stahl E., Dahl O., Wicklund H., Unsgaard B., Baldetorp L., Ahlström S., Fosså S. D. Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience. J Clin Oncol. 1991 May;9(5):818–826. doi: 10.1200/JCO.1991.9.5.818. [DOI] [PubMed] [Google Scholar]
  2. Bajorin D. F., Geller N. L., Bosl G. J. Assessment of risk in metastatic testis carcinoma: impact on treatment. Urol Int. 1991;46(3):298–303. doi: 10.1159/000282155. [DOI] [PubMed] [Google Scholar]
  3. Dearnaley D. P., Horwich A., A'Hern R., Nicholls J., Jay G., Hendry W. F., Peckham M. J. Combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for metastatic testicular teratoma: long-term follow-up. Eur J Cancer. 1991;27(6):684–691. doi: 10.1016/0277-5379(91)90166-b. [DOI] [PubMed] [Google Scholar]
  4. Donohue J. P., Rowland R. G., Kopecky K., Steidle C. P., Geier G., Ney K. G., Einhorn L., Williams S., Loehrer P. Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer. J Urol. 1987 Jun;137(6):1176–1179. doi: 10.1016/s0022-5347(17)44439-9. [DOI] [PubMed] [Google Scholar]
  5. Donohue J. P., Rowland R. G. The role of surgery in advanced testicular cancer. Cancer. 1984 Dec 1;54(11 Suppl):2716–2721. doi: 10.1002/1097-0142(19841201)54:2+<2716::aid-cncr2820541418>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  6. Einhorn L. H. Treatment of testicular cancer: a new and improved model. J Clin Oncol. 1990 Nov;8(11):1777–1781. doi: 10.1200/JCO.1990.8.11.1777. [DOI] [PubMed] [Google Scholar]
  7. Fosså S. D., Qvist H., Stenwig A. E., Lien H. H., Ous S., Giercksky K. E. Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses? J Clin Oncol. 1992 Apr;10(4):569–573. doi: 10.1200/JCO.1992.10.4.569. [DOI] [PubMed] [Google Scholar]
  8. Geller N. L., Bosl G. J., Chan E. Y. Prognostic factors for relapse after complete response in patients with metastatic germ cell tumors. Cancer. 1989 Feb 1;63(3):440–445. doi: 10.1002/1097-0142(19890201)63:3<440::aid-cncr2820630308>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  9. Harding M. J., Brown I. L., MacPherson S. G., Turner M. A., Kaye S. B. Excision of residual masses after platinum based chemotherapy for non-seminomatous germ cell tumours. Eur J Cancer Clin Oncol. 1989 Dec;25(12):1689–1694. doi: 10.1016/0277-5379(89)90336-2. [DOI] [PubMed] [Google Scholar]
  10. Jansen R. L., Sylvester R., Sleyfer D. T., ten Bokkel Huinink W. W., Kaye S. B., Jones W. G., Keizer J., van Oosterom A. T., Meyer S., Vendrik C. P. Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at postchemotherapy surgery. EORTC Genitourinary Tract Cancer Cooperative Group (EORTC GU Group) Eur J Cancer. 1991;27(6):695–698. doi: 10.1016/0277-5379(91)90168-d. [DOI] [PubMed] [Google Scholar]
  11. Levitt M. D., Reynolds P. M., Sheiner H. J., Byrne M. J. Non-seminomatous germ cell testicular tumours: residual masses after chemotherapy. Br J Surg. 1985 Jan;72(1):19–22. doi: 10.1002/bjs.1800720109. [DOI] [PubMed] [Google Scholar]
  12. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966 Mar;50(3):163–170. [PubMed] [Google Scholar]
  13. Mead G. M., Stenning S. P., Parkinson M. C., Horwich A., Fossa S. D., Wilkinson P. M., Kaye S. B., Newlands E. S., Cook P. A. The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party. J Clin Oncol. 1992 Jan;10(1):85–94. doi: 10.1200/JCO.1992.10.1.85. [DOI] [PubMed] [Google Scholar]
  14. Mulders P. F., Oosterhof G. O., Boetes C., de Mulder P. H., Theeuwes A. G., Debruyne F. M. The importance of prognostic factors in the individual treatment of patients with disseminated germ cell tumours. Br J Urol. 1990 Oct;66(4):425–429. doi: 10.1111/j.1464-410x.1990.tb14967.x. [DOI] [PubMed] [Google Scholar]
  15. Newlands E. S., Reynolds K. W. The role of surgery in metastatic testicular germ cell tumours (GCT). Br J Cancer. 1989 Jun;59(6):837–839. doi: 10.1038/bjc.1989.177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Peckham M. Testicular cancer. Acta Oncol. 1988;27(4):439–453. doi: 10.3109/02841868809093570. [DOI] [PubMed] [Google Scholar]
  17. Stoter G., Koopman A., Vendrik C. P., Struyvenberg A., Sleyfer D. T., Willemse P. H., Schraffordt Koops H., van Oosterom A. T., ten Bokkel Huinink W. W., Pinedo H. M. Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin. J Clin Oncol. 1989 Aug;7(8):1099–1104. doi: 10.1200/JCO.1989.7.8.1099. [DOI] [PubMed] [Google Scholar]
  18. Tait D., Peckham M. J., Hendry W. F., Goldstraw P. Post-chemotherapy surgery in advanced non-seminomatous germ-cell testicular tumours: the significance of histology with particular reference to differentiated (mature) teratoma. Br J Cancer. 1984 Nov;50(5):601–609. doi: 10.1038/bjc.1984.226. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES